thalidomide has been researched along with B16 Melanoma in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Since thalidomide exhibits low oral bioavailability due to limitations in solubility, inclusion complexation using sulfobutyl ether-7 beta-cyclodextrin was used to improve the delivery of thalidomide." | 1.35 | Molecular encapsulation of thalidomide with sulfobutyl ether-7 beta-cyclodextrin for immediate release property: enhanced in vivo antitumor and antiangiogenesis efficacy in mice. ( Juvekar, A; Kale, R; Saraf, M; Tayade, P, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shah, JH | 1 |
| Swartz, GM | 1 |
| Papathanassiu, AE | 1 |
| Treston, AM | 1 |
| Fogler, WE | 1 |
| Madsen, JW | 1 |
| Green, SJ | 1 |
| Fujiwara, Y | 1 |
| Sun, Y | 1 |
| Torphy, RJ | 1 |
| He, J | 1 |
| Yanaga, K | 1 |
| Edil, BH | 1 |
| Schulick, RD | 1 |
| Zhu, Y | 1 |
| Lu, L | 1 |
| Payvandi, F | 1 |
| Wu, L | 1 |
| Zhang, LH | 1 |
| Hariri, RJ | 1 |
| Man, HW | 1 |
| Chen, RS | 1 |
| Muller, GW | 2 |
| Hughes, CC | 1 |
| Stirling, DI | 2 |
| Schafer, PH | 1 |
| Bartlett, JB | 1 |
| Kale, R | 1 |
| Tayade, P | 1 |
| Saraf, M | 1 |
| Juvekar, A | 1 |
| Dredge, K | 1 |
| Marriott, JB | 1 |
| Todryk, SM | 1 |
| Chen, R | 1 |
| Dalgleish, AG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer After First-line Chemotherapy[NCT02018523] | Phase 1 | 7 participants (Actual) | Interventional | 2014-06-30 | Terminated (stopped due to Study did not enroll enough subjects to make a statistically sound conclusion.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 other studies available for thalidomide and B16 Melanoma
| Article | Year |
|---|---|
Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor metastasis.
Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Glutarates; Indoles; Lung Neoplasm | 1999 |
Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity.
Topics: Animals; Antineoplastic Agents; B7-H1 Antigen; Cell Line, Tumor; Cytotoxicity, Immunologic; Gene Exp | 2018 |
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.
Topics: Adherens Junctions; Angiogenesis Inhibitors; Animals; Antigens, CD; Antineoplastic Agents; Basic Hel | 2009 |
Molecular encapsulation of thalidomide with sulfobutyl ether-7 beta-cyclodextrin for immediate release property: enhanced in vivo antitumor and antiangiogenesis efficacy in mice.
Topics: Angiogenesis Inhibitors; Animals; beta-Cyclodextrins; Biological Availability; Calorimetry, Differen | 2008 |
Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity.
Topics: Adjuvants, Immunologic; Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; B7-1 | 2002 |